Prior anti-BCMA antibody-drug conjugate exposure does not impact long-term outcomes with subsequent anti-BCMA T-cell-engaging bispecific antibodies: a singlecenter real-world data analysis

Giuseppe Bertuglia; Elisa Seneca; Elilta Samuel; Christina Messiou; Simon Stern; Tommy Brown; Leonora Conneely; Tracy Thornton; Dima El‐Sharkawi; Mikel Valganon Petrizan; Katy Smith; Francesca Gay; Charlotte Pawlyn; Kevin Boyd; Martin Kaiser

doi:10.3324/haematol.2026.301383

August 27, 2026HaematologicaOpen Access

Prior anti-BCMA antibody-drug conjugate exposure does not impact long-term outcomes with subsequent anti-BCMA T-cell-engaging bispecific antibodies: a singlecenter real-world data analysis

View Full Paper

Ask AI

Bookmark

Share

Key Points

To determine whether prior exposure to anti-BCMA antibody-drug conjugates negatively impacts the long-term clinical outcomes of patients subsequently treated with anti-BCMA T-cell-engaging bispecific antibodies.
Single-center real-world data analysis of patients with multiple myeloma treated with anti-BCMA T-cell-engaging bispecific antibodies.
Comparison of long-term therapeutic outcomes stratified by prior exposure versus non-exposure to anti-BCMA antibody-drug conjugates.
Prior exposure to anti-BCMA antibody-drug conjugates did not significantly impair long-term efficacy outcomes following subsequent anti-BCMA bispecific antibody therapy.
Sequential anti-BCMA therapy demonstrated sustained anti-tumor activity without clinical evidence of cross-resistance compromising patient survival.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Real-world single-center study shows preserved long-term efficacy of anti-BCMA bispecific antibodies after prior conjugate therapy in myeloma, indicating sequential targeting remains viable.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bertuglia et al. (2026) studied this question.

synapsesocial.com/papers/6a9299ac8e5d7d1fc0c11be9 https://doi.org/10.3324/haematol.2026.301383

View Full Paper

Ask AI

Bookmark

Share

Prior anti-BCMA antibody-drug conjugate exposure does not impact long-term outcomes with subsequent anti-BCMA T-cell-engaging bispecific antibodies: a singlecenter real-world data analysis

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Prior anti-BCMA antibody-drug conjugate exposure does not impact long-term outcomes with subsequent anti-BCMA T-cell-engaging bispecific antibodies: a singlecenter real-world data analysis

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Keep reading

Keep reading